Biotech entity
Every one of those 2 sits in a single category, pharma. NHS is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The 14-day window averages about 1 story each week. Each story carries 7 original sources on average, compared with 3.5 for the broader beat in this window.
Last mentioned: Mar 19, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, pharma. NHS is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The 14-day window averages about 1 story each week. Each story carries 7 original sources on average, compared with 3.5 for the broader beat in this window. The 6.5 average consequence score is above the beat benchmark of 6.1 in the same window. This profile follows 2 Biotech stories mentioning Department of Health and Social Care across the period from March 6, 2026 to March 19, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 206 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Department of Health and Social Care. Shared-story counts are live from our verified record — not editorial picks.
Scheduled Re-evaluation
NICE appraisal committee is set to meet for a second round of evidence review.
NHS Impact Probe
The inquiry sets out detailed evidence regarding the pandemic's impact on NHS patients and staff.
Public Campaign Launch
Bereaved family launches a national campaign imploring the NHS to reconsider the approval.
NICE Initial Review
NICE issues a preliminary recommendation against the drug due to cost-effectiveness concerns.
FDA Approval
The treatment receives accelerated approval in the United States for aggressive cancer types.
Module 3 Hearings Begin
Public hearings start for the module focused on the impact on healthcare systems.
Inquiry Established
The UK COVID-19 Inquiry is formally set up to examine the UK's response to the pandemic.
First National Lockdown
UK government imposes stay-at-home orders, significantly impacting NHS service delivery.
The UK’s public inquiry into the COVID-19 pandemic has entered a critical phase, examining the systemic impact on the National Health Service (NHS) and patient outcomes. This module scrutinizes healthcare capacity, the management of non-COVID services, and the effectiveness of medical interventions during the crisis.
A bereaved family's public campaign has reignited a national debate over the NHS's drug appraisal process for aggressive cancers. The movement highlights the growing tension between fiscal cost-effectiveness and the urgent need for life-extending therapies already available in other markets.
Source: surreycomet.co.uk · burytimes.co.uk
Department of Health and Social Care is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
